Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

T cell receptor recognizing NY-ESO-1 antigen short peptide

A cell receptor, cell technology, applied in the field of TCR, can solve problems such as normal cell damage

Inactive Publication Date: 2016-12-07
GUANGDONG XIANGXUE LIFE SCI LTD
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For the treatment of the above diseases, methods such as chemotherapy and radiotherapy can be used, but all of them will cause damage to their own normal cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • T cell receptor recognizing NY-ESO-1 antigen short peptide
  • T cell receptor recognizing NY-ESO-1 antigen short peptide
  • T cell receptor recognizing NY-ESO-1 antigen short peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0129] Example 1 Cloning NY-ESO-1 Antigen Short Peptide-Specific T Cells

[0130]Peripheral blood lymphocytes (PBL) from healthy volunteers with the genotype HLA-A0201 were stimulated with the synthetic short peptide SLLMWITQC (Beijing Saibaisheng Gene Technology Co., Ltd.). The pHLA haploid was prepared by annealing SLLMWITQC short peptide with biotin-labeled HLA-A*0201. These haploids were combined with PE-labeled streptavidin (BD Company) to form PE-labeled tetramers, and the tetramers and anti-CD8-APC double-positive cells were sorted. Sorted cells were expanded and subjected to secondary sorting as described above, followed by monoclonalization by limiting dilution. Monoclonal cells were stained with tetramers, and the double-positive clones screened were as follows: image 3 shown.

Embodiment 2

[0131] Example 2 Obtaining the TCR gene and carrier construction of NY-ESO-1 antigen short peptide-specific T cell clone

[0132] with Quick-RNA TM MiniPrep (ZYMO research) extracted the total RNA of the short antigen peptide SLLMWITQC-specific and HLA-A0201-restricted T cell clones screened in Example 1. The cDNA was synthesized using clontech's SMART RACE cDNA amplification kit, and the primers used were designed at the C-terminal conserved region of the human TCR gene. The sequence was cloned into T vector (TAKARA) for sequencing. It should be noted that this sequence is complementary and does not contain introns. After sequencing, the sequence structures of the TCR α chain and β chain expressed by the double-positive clone are shown in Figure 1 and Figure 2, respectively. Figure 1a , Figure 1b , Figure 1c , Figure 1d , Figure 1e with Figure 1f They are the amino acid sequence of TCRα chain variable domain, the nucleotide sequence of TCRα chain variable domain,...

Embodiment 3

[0142] Example 3 Expression, refolding and purification of NY-ESO-1 antigen short peptide-specific soluble TCR

[0143] In order to obtain a soluble TCR molecule, the α and β chains of the TCR molecule of the present invention may only include their variable domains and part of the constant domains respectively, and a cysteine ​​residue is introduced into the constant domains of the α and β chains respectively To form an artificial interchain disulfide bond, the positions of the introduced cysteine ​​residues are Thr48 of TRAC*01 exon 1 and Ser57 of TRBC2*01 exon 1; the amino acid sequence and nucleotides of the α chain sequence as Figure 4a with Figure 4b As shown, the amino acid sequence and nucleotide sequence of its β chain are as follows Figure 5a with Figure 5b The introduced cysteine ​​residues are indicated in bold letters. The target gene sequences of the above TCRα and β chains were synthesized and inserted into the expression vector pET28a+ (Novagene ), the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a T cell receptor (TCR) which can be specifically combined with an NY-ESO-1 antigen short peptide SLLMWITQC. The antigen short peptide SLLMWITQC and HLA A0201 can form a composite which is presented onto the surface of the cells together. The invention also provides a nucleic acid molecule encoding the TCR and a carrier containing the nucleic acid molecule, and also provides a cell that transduces the TCR.

Description

technical field [0001] The present invention relates to a TCR capable of recognizing short peptides derived from the NY-ESO-1 antigen. The present invention also relates to NY-ESO-1 specific T cells obtained by transducing the above TCR, and their role in the prevention and treatment of NY-ESO- 1 Use in related diseases. Background technique [0002] NY-ESO-1 belongs to the cancer-testis antigen (Cancer-Testis Antigen, CTA) family, which can be expressed in testis, ovarian tissue and many different types of tumor tissues, but not in other normal tissues. strong tumor antigens. NY-ESO-1 is an endogenous antigen, which is degraded into small molecular polypeptides after being produced in cells, and combines with MHC (major histocompatibility complex) molecules to form a complex, which is presented to the cell surface. SLLMWITQC(157-165) is a short peptide derived from NY-ESO-1 antigen and is a target for the treatment of NY-ESO-1 related diseases. Studies have shown that NY...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/725C12N15/12C12N15/867C12N5/10A61K38/17A61K48/00A61K35/17A61P35/00A61P37/02
CPCA61K38/17A61K48/00C12N5/10C12N15/867A61K39/4611A61K39/4632A61K39/464488
Inventor 李懿区裕升吴万里
Owner GUANGDONG XIANGXUE LIFE SCI LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com